Childhood interstitial lung diseases (chILDs) are rare and heterogeneous diseases with
significant morbidity and mortality. An accurate and quick aetiological diagnosis may …

Background Childhood interstitial lung disease (ILD) comprises a spectrum of rare ILDs
affecting infants, children and adolescents. Nintedanib is a licensed treatment for pulmonary …

Computed tomography (CT) imaging findings of pulmonary fibrosis are well established for
adults and have been shown to correlate with prognosis and outcome. Recognition of …

The childhood interstitial lung diseases (chILD) Turkey registry (chILD-TR) was established
in November 2021 to increase awareness of disease, and in collaboration with the centers …

Background Persistent tachypnea of infancy (PTI) is the most common interstitial lung
disease in young children. As no standardized therapeutic guidelines exist, different …

Background Paediatric diffuse alveolar haemorrhage (DAH) is a rare heterogeneous
condition with limited knowledge on clinical presentation, treatment and outcome. Methods …

Background Recently, the development of advanced, noninvasive methods has allowed the
study of respiratory function even in uncooperative infants. To date, there is still little data on …

Background Children's interstitial lung disease (chILD) is a rare and potentially life‐
threatening condition. For many chILD conditions, systemic corticosteroids (sCCS) are …

Interstitial lung disease (ILD) comprises a group of respiratory diseases affecting the
interstitium of the lungs, which occur when a lung injury triggers an abnormal healing …

Background The rarity of childhood interstitial lung disease (chILD) makes it challenging to
conduct powered trials. In the InPedILD trial, among 39 children and adolescents with …